You are here:Home-Research Areas-Inflammation/Autoimmune Disease-Psoriasis

Request The Product List ofPsoriasis Psoriasis

Cat. No. Product Name CAS No. Information
PC-61603

Mapracorat

887375-26-0

Mapracorat (ZK 245186) is a potent, selective and non-steroid glucocorticoid receptor (GR) agonist with binding Ki of 1.9 nM; does not show significant activity for ERα, PR, AR or MR; shows anti-inflammatory efficacy after topical application similar to the classical glucocorticoids, with a better safety profile.

Psoriasis

Phase 1 Clinical

PC-61393

Parimifasor

1796641-10-5

Parimifasor(LYC-30937-EC, LYC30937) is an orally bioavailable, enteric-coated ATPase modulator as a gut-directed therapy for the treatment of inflammatory bowel disease (IBD).

Psoriasis

Phase 2 Clinical

PC-60508

Delgocitinib

1263774-59-9
Delgocitinib (JTE-052, LEO 124249) is a potent, selective, orally active, pan-JAK inhibitor with IC50 of 2.8, 2.6, 13 and 58 nM for JAK1,2,3 and Tyk2, respectively; does not inhibit a broad panel of kinases with exception of ROCK-II (IC50=140 nM); inhibits cytokine signaling evoked by IL-2, IL-6, IL-23, granulocyte/macrophage CSF, and IFN-α in vitro; potently suppresses the IL-2-induced IFN-γ production in mice (ED50=1.1 mg/kg), suppresses inflammatory responses in collagen-induced arthritis model.
 
Psoriasis
 
Phase 2 Clinical
PC-60455

GSK 2981278

1474110-21-8

GSK 2981278 (GSK2981278) is a potent, highly selective RORγ/RORγt inhibitor that potently inhibits IL-17A and IL-22 protein secretion in human peripheral T cell with IC50 of 3.2 nM; shows no effects on RORα-dependent activation; robustly inhibits RORγ-mediated cytokine production at both the mRNA and protein level, inhibits RORγt-mediated transactivation; attenuates inflammation in mouse model of psoriasis.

Psoriasis

Phase 2 Clinical

PC-60452

VTP-43742

1802706-04-2

VTP-43742 (VTP43742) is a highly potent, selective, oral RORγt inverse agonist for the treatment of autoimmune disorders, including multiple sclerosis and psoriasis.

Psoriasis

Phase 2 Clinical

PC-60312

PF-06263276

1421502-62-6

PF-06263276 (PF06263276, PF 6263276) is a potent, selective pan JAK inhibitor with IC50 of 2.2, 23.1, 59.9 and 29.7 nM for JAK1, JAK2, JAK3, and TYK2, respectively; demonstrates good JAK potency and kinase selectivity, exhibts inhibitory potency in human whole blood versus various stimulatory cytokines (IFNα, IL-23, IL-4, IL-6 and GM-CSF) with IC50 of 0.6-5.2 uM; suitable for inhaled and topical delivery in vivo.

Psoriasis

Phase 1 Discontinued

PC-45071

Seletalisib

1362850-20-1

Seletalisib (UCB-5857) is a potent, ATP-competitive, and selective PI3Kδ inhibitor with IC50 of 12 nM; shows significant selectivity to PI3Kδ with respect to the other class I PI3K isoforms (204-303 fold); blocks AKT phosphorylation following activation of the B-cell receptor in a B-cell line; blocks human T-cell production of several cytokines from activated T-cells, and inhibits B-cell proliferation and cytokine release; dose-dependently inhibits anti-CD3-antibody-induced interleukin 2 release in mice.

Psoriasis

Phase 3 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com